A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer

IntroductionIn a literature meta-analysis, we showed survival benefits for regimens including cisplatin [hazard ratio (HR) 0.61; 95% confidence interval (CI), 0.57–0.66] and for those including etoposide (HR 0.65; 0.61–0.69). That benefit was mainly observed when etoposide alone or in combination wi...

Full description

Bibliographic Details
Main Authors: Thierry Berghmans, Arnaud Scherpereel, Anne-Pascale Meert, Vicente Giner, Jacques Lecomte, Jean-Jacques Lafitte, Nathalie Leclercq, Marianne Paesmans, Jean-Paul Sculier, for the European Lung Cancer Working Party (ELCWP)
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-09-01
Series:Frontiers in Oncology
Subjects:
small-cell lung cancer
chemotherapy
cisplatin
etoposide
extensive disease
Online Access:http://journal.frontiersin.org/article/10.3389/fonc.2017.00217/full

Internet

http://journal.frontiersin.org/article/10.3389/fonc.2017.00217/full

Similar Items